Nevertheless, the translation of these results into the clinic may open a new avenue to evaluate the efficacy of VP3.15 also in pediatric glioma patients, where Gal9/TIM3 signaling has recently been proven to be a bona fide target [56] and PTEN is rarely mutated. The gene discussed is HAVCR2; the disease is central nervous system cancer.